Mosapramine, formerly known as Clospipramine and Y-516, is a dopamine D2-receptor antagonist used for the treatment of schizophrenia. The affinities of mosapramine for D4 receptors is 8 times higher than that of clozapine, and the affinity for D3 receptors is 40 times higher than that of raclopride. References: Kishi T, Matsunaga S, Matsuda Y, Iwata N. Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine. Neuropsychiatr Dis Treat. 2014 Dec 10;10:2339-51. doi: 10.2147/NDT.S73464. eCollection 2014. PubMed PMID: 25525363; PubMed Central PMCID: PMC4266422.

纯度：≥98%

CAS：89419-40-9